ABUS - Any thoughts on value of ABUS if this patent dispute holds up. If Moderna’s vaccine gets anywhere near the $10 billion to $20 billion annual revenue estimate recently provided by Jefferies analyst Michael Yee and ABUS gets 2%.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.